Biotricity Inc. (BTCY): Shareholders' Equity
-$34.68M
As of 2026-03-31
-$35.41M
As of 2026-06-30
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | -$34.68M | n/m | 2026-07-14, Balance as of period end |
| 2025-03-31 | -$32.01M | n/m | 2026-07-14, Balance as of period end |
| 2024-03-31 | -$31.47M | n/m | 2025-07-18, Balance as of period end |
| 2023-03-31 | -$19.85M | n/m | 2024-06-27, Balance as of period end |
| 2022-03-31 | -$2.14M | n/m | 2023-06-29, Balance as of period end |
| 2021-03-31 | -$6.83M | n/m | 2022-07-14, Balance as of period end |
| 2020-03-31 | -$3.00M | n/m | 2021-06-22, Balance as of period end |
| 2019-03-31 | -$1.78M | n/m | 2020-07-15, Balance as of period end |
| 2018-03-31 | $173.2K | n/m | 2019-07-16, Balance as of period end |
| 2017-03-31 | -$4.38M | n/a | 2018-07-13, Balance as of period end |
| 2016-12-31 | -$4.07M | n/m | 2017-03-30, Balance as of period end |
| 2015-12-31 | -$1.24M | n/a | 2017-03-30, Balance as of period end |
| 2015-08-31 | -$243.6K | n/m | 2016-04-13, Balance as of period end |
| 2014-08-31 | -$170.6K | n/a | 2015-11-30, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Biotricity Inc. (BTCY) | 2026-03-31 | -$34.68M | n/m |
| Profound Medical Corp. (PROF) | 2025-12-31 | $66.43M | +10.0% |
| Allurion Technologies, Inc. (ALUR) | 2025-12-31 | -$77.19M | n/m |
| Vivos Therapeutics, Inc. (VVOS) | 2025-12-31 | -$1.49M | n/m |
| Nephros Inc (NEPH) | 2025-12-31 | $10.20M | +18.8% |
| Sonoma Pharmaceuticals, Inc. (SNOA) | 2026-03-31 | $3.10M | -29.8% |
| Spectral AI, Inc. (MDAI) | 2025-12-31 | -$5.73M | n/m |
| DarioHealth Corp. (DRIO) | 2025-12-31 | $67.92M | -5.7% |
| Nexgel, Inc. (NXGL) | 2025-12-31 | $4.46M | -22.5% |
Compare BTCY, PROF, ALUR, VVOS side by side · Screen every company in Surgical & Medical Instruments & Apparatus ↗